Cancer treatment
Recent research on liver hepatocellular carcinoma (LIHC) has provided significant insights into the role of Charged Multivesicular Body Protein 4A (CHMP4A) in its progression. According to a study published in Frontiers in Immunology, CHMP4A is overexpressed in LIHC specimens and is associated with poor patient outcomes. The study investigated the
Cancer
The field of oncology has witnessed a paradigm shift with the advent of immunotherapy, which has brought new hope to cancer patients. However, despite its promising results, immunotherapy still faces significant challenges in terms of low response rates and severe side effects. Recent research from Wuhan University has shed light
Cancer
The field of oncology has witnessed a paradigm shift with the advent of immunotherapy, which has brought new hope to cancer patients. However, despite its promising results, immunotherapy still faces significant challenges in terms of low response rates and severe side effects. Recent research from Wuhan University has shed light
Cancer
A study published in the Cancer journal has found that patients experiencing severe side-effect bother during cancer treatment are more likely to discontinue their therapy. The research, conducted by investigators at Northwestern University Feinberg School of Medicine, analyzed data from four clinical trials involving patients with breast cancer, melanoma, and
Cancer treatment
Researchers from the Southern University of Science and Technology (SUSTech) have made a significant advancement in cancer therapy by developing a biohybrid system that combines bacterial-based targeting with immune activation. The system, called P/L@EcN, utilizes copper-free azide-alkyne click chemistry to conjugate ROS-responsive, ruxotemitide (LTX-315)-loaded poly(ethylene glycol)
Bacteria
Researchers from the Southern University of Science and Technology (SUSTech) have made a significant advancement in cancer therapy by developing a biohybrid system that combines bacterial-based targeting with immune activation. The system, called P/L@EcN, utilizes copper-free azide-alkyne click chemistry to conjugate ROS-responsive, ruxotemitide (LTX-315)-loaded poly(ethylene glycol)
Cancer treatment
According to a patent filed on November 16, 2022, and published online on October 14, 2025, a team of inventors from South Korea has developed a personalized electric field cancer treatment method and device. This innovative approach aims to improve cancer treatment efficiency by predicting optimal conditions for each patient
Cancer treatment
Boston Scientific Scimed Inc. has been issued patent number 12440258 for a novel method of treating prostate cancer, according to a report from NewsRx. The patent, filed on November 20, 2023, and published online on October 14, 2025, describes a method for treating prostate cancer using a vapor delivery needle
Cancer
A study published in the Cancer journal has found that patients experiencing severe side-effect bother during cancer treatment are more likely to discontinue their therapy. The research, conducted by investigators at Northwestern University Feinberg School of Medicine, analyzed data from four clinical trials involving patients with breast cancer, melanoma, and
Cancer treatment
Recent research on liver hepatocellular carcinoma (LIHC) has provided significant insights into the role of Charged Multivesicular Body Protein 4A (CHMP4A) in its progression. According to a study published in Frontiers in Immunology, CHMP4A is overexpressed in LIHC specimens and is associated with poor patient outcomes. The study investigated the
Cancer treatment
Recent research on liver hepatocellular carcinoma (LIHC) has provided significant insights into the role of Charged Multivesicular Body Protein 4A (CHMP4A) in its progression. According to a study published in Frontiers in Immunology, CHMP4A is overexpressed in LIHC specimens and is associated with poor patient outcomes. The study investigated the
Cancer
The field of oncology has witnessed a paradigm shift with the advent of immunotherapy, which has brought new hope to cancer patients. However, despite its promising results, immunotherapy still faces significant challenges in terms of low response rates and severe side effects. Recent research from Wuhan University has shed light
